Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.8413
-0.0321-3.68%
Volume:2.19M
Turnover:1.86M
Market Cap:233.13M
PE:-7.57
High:0.8600
Open:0.8521
Low:0.8372
Close:0.8734
52wk High:3.20
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:0.87
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.05%
PB:9.32
PE(LYR):-40.48

Loading ...

Akebia Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $49.128M Beat $48.861M Estimate

Benzinga Earnings
·
Aug 06

Akebia Therapeutics Inc Expected to Post a Loss of 4 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Akebia Grants 2 New Hires Options for 61,000 Shares at $1.32 Each

Reuters
·
Aug 04

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Akebia Initiates Phase 2 Basket Trial of Complement Inhibitor Ebribafusp in Rare Kidney Diseases

Reuters
·
Aug 03

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

THOMSON REUTERS
·
Aug 03

Akebia Therapeutics Schedules Quarterly Results Release, Conference Call

Reuters
·
Jul 29

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
Jul 29

Monopar Adds Ex-kalvista CCO Nicole Sweeny to Board

Reuters
·
Jul 20

Akebia Grants 125,600 Inducement Stock Options to New Hires at USD 1.14 a Share

Reuters
·
Jul 03

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Akebia Therapeutics Price Target Maintained with a $6.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 01

Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Akebia Therapeutics (AKBA)

TIPRANKS
·
Jul 01

Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis

MT Newswires Live
·
Jun 30

Akebia Therapeutics - Usrc Kidney Research Stops Voice Trial After Interim Analysis Shows Improved Safety with Vafseo

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics - Voice Trial Meets Stopping Criteria with Win Odds of 1.16 as of June 1, 2026

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics - no Significant Difference in Mortality: Vafseo 8.77% vs Esa 8.78% Per 100 Patient-years

THOMSON REUTERS
·
Jun 30

Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch

Simply Wall St.
·
Jun 24

Akebia Therapeutics shareholders approved authorized share increase amendment at annual meeting

Reuters
·
Jun 23

Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease

MT Newswires Live
·
Jun 10